BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10989243)

  • 1. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study.
    Wildemeersch D; Schacht E
    Maturitas; 2000 Jul; 36(1):63-8. PubMed ID: 10989243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
    Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
    Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E; Wildemeersch P
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraception with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):234-40. PubMed ID: 11245550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
    Wildemeersch D; Schacht E; Wildemeersch P; Calleweart K; Pylyser K; De Wever N
    Maturitas; 2004 May; 48(1):65-70. PubMed ID: 15223110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study.
    Wildemeersch D; Schacht E; Wildemeersch P
    Contraception; 2002 Aug; 66(2):93-9. PubMed ID: 12204781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women.
    Wildemeersch D; Schacht E; Wildemeersch P
    Maturitas; 2003 Mar; 44(3):237-45. PubMed ID: 12648887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
    Varila E; Wahlström T; Rauramo I
    Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Obstet Gynecol Reprod Biol; 2002 Apr; 102(1):74-9. PubMed ID: 12039094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.
    Wildemeersch D; Pylyser K; De Wever N; Pauwels P; Tjalma W
    Maturitas; 2007 Jun; 57(2):205-9. PubMed ID: 17227699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
    Wildemeersch D
    Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
    Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
    Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.